Article
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
28 Sept 2010
Abstract excerpt
More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human pathogen, the only approved treatment remains a combination of pegylated interferon-α and ribavirin. This rather non-specific therapy is associated with severe side effects and by far not everyone benefits from treatment. Recently, progress has been made in the development of specifically targeted antiviral therapy for HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
